| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c496ef2d3e3300de56f92d1342f4f4e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2020-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdf011b16bbb69f6c0b0eb0a7ab842f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abcf4cfa86540748394060e821055511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e697a80c63a7331e335248e617fc0296
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_275ca442c3b60745229f4775db5a8228 |
| publicationDate |
2022-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
PE-20221108-A1 |
| titleOfInvention |
OPHTHALMIC COMPOSITION OF BEVACIZUMAB |
| abstract |
IT REFERS TO AN OPHTHALMIC COMPOSITION THAT INCLUDES: A) BEVACIZUMAB IN A CONCENTRATION OF 24 MG/ML TO 26 MG/ML; B) A PHOSPHATE BUFFER IN A CONCENTRATION OF 40 mM TO 60 mM; C) A STABILIZER SUCH AS TREHALOSE IN A CONCENTRATION OF 40 MG/ML TO 70 MG/ML; AND D) A NON-IONIC SURFACTANT SUCH AS POLYSORBATE 20 IN A CONCENTRATION OF 0.2 MG/ML TO 0.6 MG/ML. SAID COMPOSITION PRESENTS FROM 1 TO 50 PARTICLES ?10 ?M IN DIAMETER PER ML, AND THE LIMITS OF THE BACTERIAL ENDOTOXIN ASSAY (BET) IN THE INTERVAL OF 0.001 TO 0.4 EU/MG. IT ALSO REFERS TO A PREPARATION PROCESS OF SAID COMPOSITION. |
| priorityDate |
2019-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |